SI
MYGN icon

Stephens Inc’s Myriad Genetics MYGN Stock Holding History

Stephens Inc’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-42,647
Closed -$1.22M – 1181
2019
Q3 		$1.22M Sell
42,647
-5,720
-12% -$167K 0.03% 507
2019
Q2 		$1.34M Buy
48,367
+1,997
+4% +$56.4K 0.03% 503
2019
Q1 		$1.54M Buy
46,370
+4,201
+10% +$128K 0.04% 465
2018
Q4 		$1.23M Sell
42,169
-3,389
-7% -$122K 0.03% 469
2018
Q3 		$2.1M Buy
+45,558
New +$2.03M 0.05% 393
2017
Q3 		– Sell
-307,413
Closed -$7.94M – 812
2017
Q2 		$7.94M Sell
307,413
-70,386
-19% -$1.49M 0.27% 70
2017
Q1 		$7.25M Buy
377,799
+67,303
+22% +$1.19M 0.26% 78
2016
Q4 		$5.18M Buy
310,496
+240,340
+343% +$4.35M 0.21% 106
2016
Q3 		$1.44M Buy
70,156
+68,806
+5,097% +$1.75M 0.06% 302
2016
Q2 		$41K Sell
1,350
-3,735
-73% -$130K ﹤0.01% 740
2016
Q1 		$190K Sell
5,085
-680
-12% -$25.6K 0.01% 659
2015
Q4 		$249K Buy
5,765
+2,020
+54% +$85.3K 0.01% 592
2015
Q3 		$140K Buy
3,745
+3,220
+613% +$114K 0.01% 679
2015
Q2 		$18K Sell
525
-10,035
-95% -$341K ﹤0.01% 784
2015
Q1 		$374K Buy
10,560
+9,130
+638% +$327K 0.02% 561
2014
Q4 		$49K Buy
1,430
+265
+23% +$9.4K ﹤0.01% 774
2014
Q3 		$45K Sell
1,165
-3,405
-75% -$127K ﹤0.01% 780
2014
Q2 		$178K Buy
4,570
+3,220
+239% +$120K 0.01% 760
2014
Q1 		$46K Hold
1,350
– – ﹤0.01% 762
2013
Q4 		$28K Sell
1,350
-200
-13% -$5.06K ﹤0.01% 836
2013
Q3 		$36K Sell
1,550
-3,200
-67% -$90.9K ﹤0.01% 780
2013
Q2 		$128K Buy
+4,750
New +$138K 0.01% 683

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Stephens Inc's MYGN Position: Q4 2019 in Review

Stephens Inc sold out of Myriad Genetics (MYGN) in Q4 2019, closing a stake of 42,647 shares — an estimated $1.22M sold.

Stephens Inc first reported a position in MYGN in Q2 2013 and held it in 22 quarters. The position peaked at $7.94M in Q2 2017. 227 funds tracked by Wall St. Rank hold MYGN as of Q4 2019.

  • Stephens Inc reported no remaining Myriad Genetics position as of Q4 2019 after selling out during the quarter.
  • Stephens Inc sold 42,647 Myriad Genetics shares in Q4 2019, an estimated $1.22M.
  • Stephens Inc first reported a position in Myriad Genetics in Q2 2013 and held it in 22 quarters.
  • Stephens Inc's Myriad Genetics position peaked at $7.94M in Q2 2017.
  • 227 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2019.

Based on Stephens Inc's 13F filing for Q4 2019, filed 14 Feb 2020.